key: cord-0878904-d9gpzmbi
authors: Ali, S.; Uddin, S. Z.; Dewan, M. N.; Moniruzzaman, M.; Kabir, M. H.; Islam, M. R.; Monir, H.; Hossan, S.; Nafiz, T. N.; Rashid, R.; Imran, K. M.
title: Differential effect of corticosteroid treatment on Influenza, SARS, MERS, and SARS-CoV-2 patients: A meta-analysis and systematic review
date: 2021-03-26
journal: nan
DOI: 10.1101/2021.03.22.21254104
sha: 35d700beea9e16e332c9790d38c03195c21fc36b
doc_id: 878904
cord_uid: d9gpzmbi

Background: Corticosteroid has been used to manage inflammation caused by many diseases including respiratory viral infections. Many articles are available to support the good and bad side of this steroid use but remain inconclusive. To find some evidence about the safety of the drug, we investigated the effect of corticosteroids on the mortality of patients with respiratory viral infections including SARS-CoV-2, SARS, MERS, and Influenza. Method: We searched articles in PubMed, Scopus, Cochrane, Medline, Google Scholar, and Web of Science records using the keywords corticosteroid or viral infection or patients or control study. Mortality was the primary outcome. Result: Our selected 24 studies involving 16633 patients were pooled in our meta-analysis. Corticosteroid use and overall mortality were not significantly associated (P=0.176), but in subgroup analysis, corticosteroid use was significantly associated with lower mortality in the case of SARS (P=0.003) but was not significantly associated with mortality for Influenza (H1N1) (P=0.260) and SARS-CoV-2 (P=0.554). Further analysis using study types of SARS-CoV-2, we found that corticosteroid use was not significantly associated with mortality in the case of retrospective cohort studies (P=0.256) but was significantly associated with lower mortality in the case of randomized control trials (P=0.005). Our findings uncover how the outcome of particular drug treatment for different diseases with comparable pathogenesis may not be similar and, RCTs are sometimes required for robust outcome data. Conclusion: At the beginning of the COVID-19 pandemic, data of corticosteroid use from other viral infections along with COVID-19 observational and retrospective cohort studies created confusion of its effect, but randomized control trials showed that corticosteroid can be used to treat COVID-19 patients.

3 Keywords: Meta-analysis, systematic reviews, COVID-19, corticosteroids, SARS, MERS, 47 H1N1 influenza 48 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 63 Corticosteroids, often known as steroids, are classes of hormones secreted by the adrenal cortex, 64 including glucocorticoids (GCs) and mineralocorticoids [3] . Nevertheless, the term 65 "corticosteroids'' is commonly used to denote glucocorticoids. Corticosteroids control various 66 cellular functions such as metabolism, development, cognition, inflammation, and homeostasis 67 [4] . Corticosteroids are being used regularly in clinics to treat autoimmune and inflammatory 68 pathologies such as allergy, septic shock, asthma, rheumatoid arthritis, multiple sclerosis, and 69 inflammatory bowel disease. The adverse effects of prolonged glucocorticoid therapy are well 70 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.22.21254104 doi: medRxiv preprint 5 established and exceedingly common which limits the therapeutic benefits. Some side effects of 71 certain medical conditions after taking corticosteroid are glucose intolerance and diabetes, 72 osteoporosis and fracture, muscle wasting, central obesity, growth retardation, depression, 73 hypertension cataracts, and increased risk of viral and bacterial infections [5] . 74 To the current day, nevertheless, corticosteroids continue to be the backbone in the treatment of 75 autoimmune disorders and inflammatory diseases, and they are prescribed as an 76 immunosuppressant after organ transplantation and as lymphocytic in chemotherapeutic 77 treatments [6]. 78 79 Corticosteroids, especially glucocorticosteroids, have inhibitory properties on a wide range of 80 immune responses [7] . They are steroid hormones with extensive effects. They often exert anti-81 inflammatory and potent immune-suppressive effects when pharmacologically driven. These are 82 typically used to prevent the harmful effects of the inflammatory cascades in severe infections 83 [8] and that's why they are used to treat inflammatory diseases due to the inhibition of B cells 84 and T cells mediated immune responses [7] . To date, the immunomodulatory function of 85 glucocorticoid analogs has been difficult to discern from their untoward effects, which reflects 86 the fact that most of the activities of cortisol are regulated by a particular molecule of the nuclear 87 receptors. For the future production of more active immunosuppressive agents, a better 88 comprehension of the molecular base of steroids on the immune response is thus necessary [9] . 89 While glucocorticoids play a role in stimulating lymphocyte apoptosis and in altering leukocyte 90 movement and redistribution, the key component of their action is the suppression of cytokine 91 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Selected articles were grouped and assigned to all the authors to extract data and put into a 178 google sheet that only the corresponding author had access to. Next, those groups of articles 179 were reassigned to a different author to extract data and record in a separate google sheet. Two 180 sheets were then matched, and any discrepancies were resolved by group meetings via Zoom.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Authors were asked to extract information on authors, title, year of publication, number of 182 patient in the treatment arm, number of patient in the control arm, a corticosteroid used, placebo-183 control or not, type of study, the mortality rate (control/corticosteroid), secondary infection rate 184 (bacterial), secondary infection rate (viral), male/female (% of the total patient), male/female (% 185 of control/corticosteroid group), the mean age of the total patient, mean age of the dead patient, CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021.

appearance of statistical heterogeneity. The derSimonian-Laird estimator is used to estimating 205 between-study variance (τ 2 ) in a random-effects model. For binary data, we have calculated risk 206 ratio (RR) as a relative effect along with a 95% confidence interval (CI). On the other hand, the 207 standard mean difference (SMD) is calculated as a relative effect for continuous data along with 208 95% CI. We have conducted subgroup analysis based on different types of viruses. A funnel plot 209 is used to check the publication bias and Egger's test of the intercept is used to quantify the 210 asymmetry of the funnel plot and to perform a statistical test. First, we combined all the studies and analyzed them as a whole although it is obvious that these 242 viral diseases are different in their pathology and may not react the same but just to understand 243 from an overall point of view. We found that the mortality rate for the patients who received 244 corticosteroids was not significantly higher than that of patients who did not receive suggested that corticosteroid therapy was not significantly associated with lower mortality rate 311 when compared using different virus types and study types but was associated with lower 312 mortality rate when low bias, gold-standard RCTs were analyzed.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Observational and cohort studies prior to the COVID-19 pandemic found a negative effect of 335 corticosteroid use as we have also shown in this meta-analysis. After the pandemic, clinicians 336 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.22.21254104 doi: medRxiv preprint stated to use corticosteroid as an immunosuppressive drug to mitigate the cytokine storm but 337 again most of the cohort studies showed higher mortality in the corticosteroid use. Then, 338 randomized control trials were implemented and showed a beneficial effect of corticosteroid use.

Because results from RCTs are robust that the cohort studies, it is now evident that cohorts' prolonged ICU stay has also been revealed by another study [63] . Then Again, corticosteroids is applied after cytokine storm vs before cytokine storm but due to data limitation, it was not 381 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The author(s) disclosed that this research received no specific grant from any funding agency in 404 the public, commercial, or not-for-profit sectors. The data will be made available upon request. pneumonia: a pilot study, Eur. Respir. J. 14 (1999) 218-220.

[9] C.A. Meier, Mechanisms of immunosuppression by glucocorticoids, Eur. J. Endocrinol.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.22.21254104 doi: medRxiv preprint

Lung infection--a public health priority

416 A novel coronavirus from patients with pneumonia in China

Use of oral 419 corticosteroids in the United Kingdom

Antiinflammatory action of glucocorticoids--new mechanisms 422 for old drugs

infection: analytic strategy using propensity scores

Corticosteroid treatment in critically ill patients with 577 severe influenza pneumonia: a propensity score matching study

Effect of hydrocortisone on mortality and organ 581 support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid 582 domain randomized clinical trial

Organizing pneumonia in patients with severe respiratory 585 failure due to novel A (H1N1) influenza, Case Reports

Clinical aspects and cytokine response in 588 severe H1N1 influenza A virus infection

H1N1: viral pneumonia as a cause of acute respiratory distress 590 syndrome

Pro: the illegitimate crusade against corticosteroids for severe H1N1 592 pneumonia

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Hydrocortisone infusion for severe community-598 acquired pneumonia: a preliminary randomized study

Glucocorticosteroid in treatment of severe pneumonia

Early use of glucocorticoids was a risk factor for critical disease and death from 604 pH1N1 infection

Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis 607 of randomised controlled trials

Effects of early corticosteroid treatment on plasma SARS-610 associated Coronavirus RNA concentrations in adult patients

Direct health care costs and length 613 of hospital stay related to health care-acquired infections in adult patients based on point 614 prevalence measurements

Long-term exposure to medium-dose 617

is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint